Mast Therapeutics, Inc. (MSTX)

[crammerfool]

StreetInsider.com Press Release

http://www.streetinsider.com/Press+Releases/Biopharma+Stock+Alert+for+ADVENTRX+Pharmaceuticals+Inc.+Issued+by+Beacon+Equity/5337121.html

Biopharma Stock Alert for ADVENTRX Pharmaceuticals Inc. Issued by Beacon Equity

February 12, 2010 6:50 AM EST


DALLAS, Feb. 12, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring ADVENTRX Pharmaceuticals Inc. (AMEX: ANX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.beaconequity.com/i/ANX

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

ADVENTRX Pharmaceuticals Inc. (ANX) is a development-stage biopharmaceutical company. The Company's business is focused on in-licensing, developing and commercializing product candidates for the treatment of cancer. ANX is focused primarily on evaluating strategic options, including the sale or exclusive license of one or more of its product candidate programs, a strategic business merger and other similar transactions. Its wholly owned subsidiaries include SD Pharmaceuticals Inc. (SDP) and ADVENTRX (Europe) Ltd.

Message Board Search for ANX: http://www.boardcentral.com/boards/ANX

In the report, the analyst notes:

"For the three months ended September 30, 2009, ANX's net loss applicable to common stock was $2.7 million, or $0.02 per share, compared with a net loss applicable to common stock of $6.8 million, or $0.08 per share, for the comparable period in 2008. Included in the net loss applicable to common stock for the 2009 third quarter was a non-cash deemed dividend expense of $0.4 million incurred in connection with the Company's July and August 2009 equity financings.

"ANX earlier this week announced that, effective immediately, Brian M. Culley, previously the Company's chief business officer and a senior vice president, will serve as its CEO and Patrick L. Keran, previously the Company's general counsel, will serve as its president and COO. Keran also will continue to serve as the Company's secretary and principal financial and accounting officer."

To read the entire report visit: http://www.beaconequity.com/i/ANX

See what investors are saying about ANX at penny stock forum

BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

CONTACT: Beacon Equity Research
Jeff Bishop
(469)-252-3505
[e-mail]